 Home > Biochemistry News > Biotechnology News > A new solid tumor targeting model for bicyclic peptide coupled immunotherapy enters the clinic

A new solid tumor targeting model for bicyclic peptide coupled immunotherapy enters the clinic

 Last Update: 2021-11-12
 Source: Internet
 Author: User

Tags

passive immunotherapy agent

2a breast cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Bicycle Therapeutics announced that its tumor-targeted immune cell agonist BT7480, designed based on bicyclic peptides, has completed its first patient administration in a phase 1/2 clinical trial

Bicycle company uses bicyclic peptide technology to develop differentiated therapies

BT7480 is a potential "first-in-class" tumor-targeted immune cell agonist

▲Schematic diagram of BT7480 structure (picture source: reference [2])

In preclinical studies, BT7480 can significantly change the tumor microenvironment, stimulate the infiltration of immune cells, and eliminate Nectin-4 expressing tumors in animals without continuous administration

▲BT7480 significantly reduces the size of tumors in animals (picture source: reference [2])

This phase 1/2 open-label clinical trial will be divided into two parts.

Reference materials:

[1] Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression.

[2] Hurov et al.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express bicyclic peptide-coupled immunotherapy, a new solid tumor targeting model has entered the clinic

11-14

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

A new solid tumor targeting model for bicyclic peptide coupled immunotherapy enters the clinic

Related Articles

Express bicyclic peptide-coupled immunotherapy, a new solid tumor targeting model has entered the clinic